Results 91 to 100 of about 6,124,915 (260)

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Engineering Vanderbilt; Vol. 48 No. 02, 2007

, 2007
Engineering Vanderbilt (formerly Engineering News) is the newsletter of the Vanderbilt University School of EngineeringSchool of ...
Vanderbilt University. School of Engineering
core  

An ecological self-purification pathway: Natural lava-Rhodopseudomonas palustris synergy enables spontaneous photobioelectrocatalysis for efficient dye degradation

Ecotoxicology and Environmental Safety
Persistent synthetic dyes such as crystal violet pose substantial challenges to environmental remediation due to their high structural stability and toxicity.
Jueyu Wang, Kuo Yang, Yue Yang, Xiaomeng Huang, Daizong Cui, Min Zhao   +5 more
doaj   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Engineering Vanderbilt; Vol. 49 No. 01, 2008

, 2008
Engineering Vanderbilt (formerly Engineering News) is the newsletter of the Vanderbilt University School of EngineeringSchool of ...
Vanderbilt University. School of Engineering
core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Engineering Vanderbilt; Vol. 52, No. 02, 2011

, 2011
Engineering Vanderbilt (formerly Engineering News) is the newsletter of the Vanderbilt University School of Engineering.Vanderbilt University.
Vanderbilt University. School of Engineering
core  

A multimodal model for protein function prediction

Scientific Reports
Protein function, which is determined by sequence, structure, and other characteristics, plays a crucial role in an organism’s performance. Existing protein function prediction methods mainly rely on sequence data and often ignore structural properties ...
Yu Mao, WenHui Xu, Yue Shun, LongXin Chai, Lei Xue, Yong Yang, Mei Li   +6 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Engineering Vanderbilt; Vol. 52, No. 01, 2011

, 2011
Engineering Vanderbilt (formerly Engineering News) is the newsletter of the Vanderbilt University School of Engineering.Vanderbilt University.
Vanderbilt University. School of Engineering
core